124 related articles for article (PubMed ID: 38797087)
1. Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial.
Gundugurti PR; Banda N; Yadlapalli SSR; Narala A; Thatikonda R; Kocherlakota C; Kothapalli KS
Asian J Psychiatr; 2024 Jul; 97():104073. PubMed ID: 38797087
[TBL] [Abstract][Full Text] [Related]
2. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.
Bergamaschi MM; Queiroz RH; Chagas MH; de Oliveira DC; De Martinis BS; Kapczinski F; Quevedo J; Roesler R; Schröder N; Nardi AE; Martín-Santos R; Hallak JE; Zuardi AW; Crippa JA
Neuropsychopharmacology; 2011 May; 36(6):1219-26. PubMed ID: 21307846
[TBL] [Abstract][Full Text] [Related]
4. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
5. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing.
Narayan AJ; Downey LA; Rose S; Di Natale L; Hayley AC
J Clin Sleep Med; 2024 May; 20(5):753-763. PubMed ID: 38174873
[TBL] [Abstract][Full Text] [Related]
8. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder.
Amsterdam JD; Li Y; Soeller I; Rockwell K; Mao JJ; Shults J
J Clin Psychopharmacol; 2009 Aug; 29(4):378-82. PubMed ID: 19593179
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD).
Cutler NR; Sramek JJ; Macpherson AE; Doss MG; Benes CO; Howard SF
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):685-94. PubMed ID: 7938559
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
[TBL] [Abstract][Full Text] [Related]
12. Effects of treatment with etizolam 0.5 mg BID on cognitive performance: a 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study in patients with anxiety disorder.
De Candia MP; Di Sciascio G; Durbano F; Mencacci C; Rubiera M; Aguglia E; Garavini A; Bersani G; Di Sotto A; Placidi G; Cesana BM
Clin Ther; 2009 Dec; 31(12):2851-9. PubMed ID: 20110024
[TBL] [Abstract][Full Text] [Related]
13. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
14. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
15. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
16. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.
Johnson JR; Burnell-Nugent M; Lossignol D; Ganae-Motan ED; Potts R; Fallon MT
J Pain Symptom Manage; 2010 Feb; 39(2):167-79. PubMed ID: 19896326
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
McGuire P; Robson P; Cubala WJ; Vasile D; Morrison PD; Barron R; Taylor A; Wright S
Am J Psychiatry; 2018 Mar; 175(3):225-231. PubMed ID: 29241357
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of Shu-gan-qing-re formula for generalized anxiety disorder: study protocol for a multi-center, prospective, double-blind, double-dummy, randomized controlled trial.
Chen P; Zhu H; Ning Y; Yin D; Jia H
Trials; 2020 Mar; 21(1):266. PubMed ID: 32171323
[TBL] [Abstract][Full Text] [Related]
20. The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trial.
Gournay LR; Ferretti ML; Bilsky S; Vance E; Nguyen AM; Mann E; Williams P; Leen-Feldner EW
Psychopharmacology (Berl); 2023 Oct; 240(10):2147-2161. PubMed ID: 37552290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
